Mast Cells and Resistance to Immunotherapy in Cancer

被引：0
作者：
Domenico Ribatti
机构：
[1] University of Bari Medical School,Department of Translational Biomedicine and Neuroscience
来源：
Archivum Immunologiae et Therapiae Experimentalis | 2023年 / 71卷
关键词：
Immunotherapy; Mast cells; Resistance; Tumor growth;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Mast cells are involved in tumor growth and their mediators exert both pro- and anti-tumorigenic roles in different human cancers. The identification of defined immunosuppressive pathways that are present in the tumor microenvironment has pointed therapeutic strategies that may promote inflammation and/or innate immune activation in this context. Mast cells can contribute to the immune suppressive tumor microenvironment and may also enhance anti-tumor responses. This review article is focused on the analysis of the mechanisms of the role of mast cells in resistance to immunotherapy in cancer.
引用
收藏
相关论文
共 86 条
[1]  
Blair RJ(1997)Human mast cells stimulate vascular tube formation: tryptase is a novel potent angiogenic factor J Clin Invest 99 2691-2700
[2]  
Meng H(2012)Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia Leuk Lymphoma 53 136-142
[3]  
Marchese MJ(2015)Mast cells boost myeloid-derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment Cancer Immunol Res 3 85-95
[4]  
Byrd JC(2012)Expression of mast cell proteases correlates with mast cell maturation and angiogenesis during tumor progression PLoS ONE 7 e40790-932
[5]  
Kipps TJ(2009)Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT PLoS ONE 4 e7258-3190
[6]  
Flinn IW(2022)Human tumor targeted cytotoxic mast cells for cancer immunotherapy Front Oncol 12 871390-1279
[7]  
Danelli L(2022)Harnessing the anti-tumor mediators in mast cells as a new strategy for adoptive cell transfer for cancer Front Oncol 12 830199-565
[8]  
Frossi B(2000)Inhibition of c-kit receptor tyrosine kinase activity by STI 571 a selective tyrosine kinase inhibitor Blood 96 925-2931
[9]  
Gri G(2013)Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin J Clin Oncol 31 3182-2574
[10]  
de Souza Jr DA(2008)SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment Blood 112 1269-580
123456789